Loading
IT
Iambic Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$1.1B
Iambic Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Iambic Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. Between 18 October 2025 and 18 October 2026, 5 insiders published 5 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Insider buying of Iambic Therapeutics, Inc. has been absent for the past year. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (5,816 companies, median 19 filings), a count of 5 filings is below the norm.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
5
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
· cache
US$23.81
Analyst consensus
Income statement
EBITDA-US$98.8M
Balance sheet & cash
Market capUS$1.1B
Debt / Equity3%
Last declaration on 16 October 2026
Declarations5 total
28,400 shares0Common StockSEC:0001855980-26-000007:0
19,500 shares0Common StockSEC:0002155824-26-000005:0
31,000 shares0Common StockSEC:0001864141-26-000007:0
132,200 shares0Common StockSEC:0002156015-26-000005:0
132,200 shares0Common StockSEC:0002034921-26-000007:0
5 of 5 declarations
About Iambic Therapeutics, Inc.
Iambic Therapeutics, Inc. is a company focused on developing innovative therapies for disease treatment. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
